Aclarion Completes First Nociscan Exams in Norwegian LIFEHAB Trial
TL;DR
Aclarion's Nociscan technology provides an advantage in identifying chronic low back pain biomarkers for treatment response.
Nociscan uses Magnetic Resonance Spectroscopy to quantify biomarkers and proprietary algorithms to determine the source of pain.
Nociscan's potential to help physicians identify optimal treatment options could improve patient outcomes and reduce chronic low back pain.
Aclarion's Nociscan technology is an innovative approach using magnetic resonance spectroscopy for noninvasive disc pain evaluation.
Found this article helpful?
Share it with your network and spread the knowledge!
Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company specializing in leveraging biomarkers and augmented intelligence to identify chronic low back pain, has announced the completion of the first Nociscan exams for patients enrolled in the LIFEHAB Trial in Norway. This randomized controlled trial is studying 202 patients who have experienced low back pain for more than a year. It compares the outcomes of lumbar interbody fusion surgery with multidisciplinary rehabilitation.
The Nociscan technology was selected for its ability to evaluate how magnetic resonance spectroscopy (MRS) biomarkers can identify patient improvement following treatment. Patient enrollment for the LIFEHAB trial began in the second quarter of 2024, with the first Nociscan exams completed by six patients in late August.
Brent Ness, CEO of Aclarion, expressed optimism about the trial's progress. "We are excited to see the LIFEHAB Trial progressing on schedule and look forward to the results of the study and to the role we expect Nociscan data to play in not only helping physicians determine which discs to treat but in potentially helping to predict which treatment option is optimal for a particular patient," Ness said. He also noted that while the company aims to make Nociscan the standard of care for clinical use, the research market has been an early adopter of the technology.
Aclarion is also awaiting results from a completed trial in Rome, where Nociscan was used to evaluate regenerative technologies. Additionally, results from two NIH studies are pending, which focus on Nociscan's role in treating chronic low back pain. Chief Strategy Officer Ryan Bond emphasized the accelerated pace at which Nociscan is being adopted in the research market. "We see Nociscan moving at an accelerated pace of adoption in the research market and look forward to announcing more partnerships as we continue to drive Nociscan to what we expect to be the gold standard for determining which discs to treat in research protocols on low back pain," Bond stated.
The LIFEHAB trial is pivotal for Aclarion's long-term strategy, especially in achieving successful reimbursement in single-payer national health insurance systems like Norway's. The trial is the latest in a series of customer-sponsored clinical trials involving Nociscan, and Aclarion anticipates announcing additional partnerships as the technology gains further traction in the research market.
For more details on the LIFEHAB Trial, visit https://classic.clinicaltrials.gov/ct2/show/NCT06169488.
Curated from NewMediaWire
